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Abstract
This update reviews the remarkable progression in several cardiovascular gene transfer domains. The ﬁrst chemical gene therapy
protocols to stimulate angiogenesis in ischemic myocardium are discussed and both the great expectations as well as remaining hurdles
are highlighted. In experimental models of restenosis and heart failure gene therapy shows promising results. Important questions
regarding vector-related limitations and suboptimal in vivo delivery systems will require expeditious attention for gene therapy to become
a more widely applicable option in cardiovascular diseases. Ó 1999 Published by Elsevier Science B.V. All rights reserved.
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1. Introduction Cancer patients for whom conventional treatment failed,
might be more eager to try novel, and still incompletely
Two years ago a focus on cardiovascular gene therapy validated treatments, while many patients with car-
was published in this journal [1], in which several reviews diovascular diseases and their doctors hesitate to consider
were presented on different ﬁelds of cardiovascular medi- gene therapy. From this view point, patients suffering from
cine, where gene therapy was emerging as a novel cardiac diseases with few or no therapeutic options,
potential treatment modality. While some domains, includ- including cardiomyopathies and end-stage heart failure,
ing therapeutic angiogenesis, have progressed at a remark- might be better candidates for gene-based treatments in the
able pace, other areas are still in the phase of in vitro and near future. Also, in some areas where gene therapy
small animal research. On the other hand, the powerful appeared as a promising alternative for failing pharmaco-
gene therapy technology has contributed signiﬁcantly to a logical approaches, novel strategies are emerging. For
better understanding of cardiovascular biology. Yet many instance, the introduction of brachytherapy in the preven-
hurdles remain before gene therapy will make a noticeable tion and treatment of restenosis [3] and the advances in
impact on the treatment of cardiovascular disease: vector- percutaneous revascularization procedures might bear on
related inﬂammation, limited expression span, suboptimal possible applications of gene therapy in its current state.
delivery systems, and gene expression levels are among This update is not intended as a comprehensive over-
the major concerns. Moreover, treatment strategies are view of current research in cardiovascular gene therapy,
often based on mechanisms identiﬁed in small animal but rather as a concise update on new developments in
models, the relevance of which for patient care needs areas that were highlighted in a former focused issue of
careful consideration [2]. Cardiovascular Research in 1997 [1] and with special
emphasis on recent developments in gene therapy for
angiogenesis and vasculoproliferative diseases.
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2. Angiogenesis Nitric oxide synthase (NOS), the enzyme responsible for
endothelial NO production, might also be considered as a
The therapeutic implications of angiogenic growth have potential angiogenic factor, as both VEGF [18] and FGF
been clearly identiﬁed in recent years in different animal [19] have been shown to modulate angiogenesis in part
models [4,5], and have led to the initiation of clinical trials through the activation of NOS. Despite these exciting
in patients with coronary and peripheral vascular insuf- results two major caveats remain. First, the proof of
ﬁciency. Intramuscular injection of naked plasmid DNA concept of therapeutic angiogenesis in large animal models
encoding the 165 amino acid isoform of human vascular is a prerequisite for future gene therapy protocols in
endothelial growth factor (VEGF) induced angiogenesis patients. Second, potential side effects associated with
and decreased ischemia in patients with ischemic ulcers untoward angiogenesis need careful investigation.
due to peripheral vascular disease [6]. In a landmark study, Neoangiogenesis is indeed implicated in physiological
patients with refractory stable angina who were not as well as pathological processes including tumor and
amenable to classical revascularization received direct metastatic growth, diabetic retinopathy, and atherosclerotic
intramyocardial injections of VEGF plasmid via a mini- plaque rupture [20]. Inoue et al. [21] demonstrated that
thoracotomy [7]. Patients had reduced clinical symptoms expression of VEGF and its receptors ﬂt-1 and ﬂk-1
of angina and objective evidence of reduced ischemia as correlated with the severity of atherosclerosis in human
documented by dobutamine single photon emission com- coronary arteries. Furthermore, inhibition of angiogenesis
puted tomography (SPECT) imaging. by speciﬁc anti-angiogenic molecules reduced plaque
However, the results of these studies have to be consid- growth in an atherosclerotic mouse model [22], whereas
ered cautiously because of the absence of a control group. local administration of FGF contributed to unfavorable
Furthermore, inﬂammation caused by the vector or even arterial remodeling in injured coronary arteries [23],
the needle injections might have contributed to formation possibly due to enhanced adventitial angiogenesis and
of new capillaries. The need for a control group was also increased cellular proliferation. Another safety concern is
illustrated by the VIVA trial [8]. In this trial, patients with the use of angiogenic factors in diabetic patients, who
ischemic heart disease received placebo or intracoronary commonly suffer from diffuse coronary artery disease and
recombinant VEGF protein followed by an IV infusion. are potential candidates for therapeutic angiogenesis.
Both in the treated and the placebo group the patients’ VEGF concentrations are increased in ocular liquid of
clinical status and treadmill tests improved, but the ab- patients suffering from diabetic retinopathy [24], and
sence of a positive effect led to the premature termination VEGF inhibition in an experimental model of ischemic
of the study. Catheter-based interventional techniques will retinopathy in mice was associated with less retinopathy
undoubtedly provide an easier way to achieve myocardial [25]. Signiﬁcant circulating levels of recombinant VEGF
delivery and will facilitate inclusion of a control group. In are detected after intramuscular [6] and intramyocardial [7]
this respect, successful gene transfer was obtained using a administration which may modulate unwanted angiogen-
transmyocardial injection catheter [9]. Pericardial delivery esis at remote sites. Clearly, further basic research needs to
using a transatrial [10] or transmyocardial [11] approach clarify these safety issues, and expand our knowledge of
has also been considered for diffusable angiogenic gene therapeutic angiogenesis and vasculogenesis as new strate-
products, with the pericardial space serving as a sustained- gies for postnatal neovascularization [26].
release reservoir. An alternative approach could be to use
the percutaneous PerDUCER device [12], allowing for safe
access to the pericardial space via a minimal subxiphoid 3. Vasculoproliferative diseases
incision.
To date, the majority of gene-based experiments have Gene therapy for restenosis also progressed from the
been conducted in small animal models, predominantly in experimental phase to the ﬁrst clinical trials. To investigate
the murine ischemic hindlimb model. Decreased angio- if VEGF overexpression can accelerate re-endothelializa-
genesis in diabetic mice could be overcome by intramuscu- tion and thus reduce neointima after local vascular injury,
lar injection with adenovirus encoding VEGF [13]. New as demonstrated in a rabbit model [27],VEGF plasmid was
angiogenic growth factors are also being investigated, locally delivered to patients after PTCA using the dispatch
including hepatic growth factor (HGF) [14], leptin [15] catheter [28]. Although no ﬁnal results have been reported,
and thrombopoietin [16]. Of interest, local overexpression the method seems feasible and safe in the short term. In
of a hypoxia-inducible transcription factor has been shown another trial, antisense oligonucleotides against c-myc were
to augment blood ﬂow to an ischemic hindlimb. Hypoxia- used to prevent coronary restenosis in stented patients
inducible factor 1 (HIF-1) is a posttranscriptionally reg- (ITALICS trial) [29]. Although successful in experimental
ulated transcription factor, controlling several hypoxia- porcine studies [30], the results could not be reproduced in
inducible genes [17]. Overexpression of HIF 1-related patients in part due to methodological limitations. The
proteins might therefore induce a broader angiogenic delivery device could have been suboptimal for effective
response than overexpression of a single angiogenic factor. gene transfer in the vessel wall, and both dose–response
b
y
 
g
u
e
s
t
 
o
n
 
N
o
v
e
m
b
e
r
 
3
,
 
2
0
1
4
D
o
w
n
l
o
a
d
e
d
 
f
r
o
m
 500 P. Sinnaeve et al. / Cardiovascular Research 44 (1999) 498–506
and pharmacokinetic characteristics need a more detailed thrombosis in atherosclerotic rabbit arteries, but not in
evaluation. normal arteries, although transfection efﬁciency was simi-
Two recent reviews have extensively covered the pros lar. Although NOS overexpression in balloon-injured
[31] and the cons [2] of gene therapy for restenosis. porcine arteries reduces neointima [33], local NOS over-
Despite major advances that have led to the ﬁrst clinical expression could paradoxically contribute to neointima
trials, many hurdles remain. The difﬁculties to translate the formation in diseased [43], or balloon-injured [44] atheros-
excellent effect of many gene-based approaches in small clerotic arteries via the generation of toxic peroxynitrite
animal models of vascular injury to larger, more relevant [2]. In contrast, NOS overexpression in atherosclerotic
animal models and to patients relate to suboptimal delivery rabbit arteries might reduce mural inﬂammation and lipid
systems, and vector-associated toxicity. accumulation [45], and there are indications that NO
Essential cell-cycle regulatory proteins have been reduces neointimal hyperplasia after balloon angioplasty in
targeted to prevent neointima formation, because smooth hypercholesterolemic rabbits [46].
muscle cell (SMC) proliferation is a key component in the The current widespread use of stents has virtually
narrowing process in injured arteries [32]. In contrast, eliminated the problem of late constrictive remodeling, but
restenosis in patients is a complex biological phenomenon remains associated with in-stent restenosis. In-stent re-
involving not only SMC proliferation, but also SMC stenosis is mainly caused by a SMC hyperproliferative
migration and apoptosis, and matrix formation and degra- response [47] and overexpression of NOS [48] or GAX
dation, which contribute to remodeling. Proteins with [49] and chimeric DNA–RNA hammerhead ribozyme to
pleiotropic effects on vascular cell functions might have an proliferating cell nuclear antigen [50] were capable of
advantage to better target the response to vascular injury in signiﬁcantly inhibiting stenosis in a porcine coronary
patients than is the case with cell-cycle inhibitory proteins. injury model. Coating stents with DNA or viruses may
In this respect, overexpression of NOS [33], heme oxygen- provide an interesting alternative for local vascular gene
ase (H01) [34] and C-type natriuretic peptide (CNP) [35] transfer, obviating the need for sophisticated and expensive
have shown promising initial results, and deserve further delivery devices. High transfection efﬁciencies were re-
investigation. ported with a DNA-eluting polymer-coated stent in porcine
Local delivery via conventional interventional tech- coronary arteries [51]. Furthermore, bioresorbable mi-
niques remains the Achilles’ heel of vascular gene therapy croporous intravascular stents can be impregnated with
because of low transfection efﬁcacy. Surgical methods, virus or DNA, providing a sustained-release local reservoir
including local dwelling, are cumbersome or impossible to while still serving as an effective scaffold to the artery
perform routinely. Adventitial delivery of adenoviral vec- [52]. A few years ago, seeding of genetically modiﬁed
tors may cause less medial inﬂammation than intraluminal cells on stents was proposed as a promising technique [53],
delivery [36], potentially reducing vector-induced inﬂam- but no intracoronary applications of this approach have
mation, but requires surgical procedures or perforating been reported so far.
needle catheters [37]. Few novel devices have emerged Preventing neointimal growth in venous bypass grafts or
since a previous review in this journal more than 2 years cardiac allografts might be a particularly attractive objec-
ago [38]. Different approaches to optimize local gene tive for gene therapy, mainly because of the easy surgical
delivery have been tested. In a comparative study, three access during tissue prelevation [54]. Two years ago, the
intramural pressure-driven catheters and one mechanical authors of a review on gene therapy for the prevention of
intramural catheter were compared in a porcine coronary vein graft failure [55] regretted the lack of interest for gene
artery balloon-angioplasty model [39]. Three of the four therapy in this ﬁeld. Since then, pressure-mediated delivery
catheters tested (InfusasleeveE, CrescendoE and of E2F decoy oligonucleotide was tested in vein grafts
InﬁltratorE) demonstrated comparable efﬁciency as re- [56], and was associated with decreased primary vein graft
ﬂected by vascular luciferase gene expression levels. failure [57]. Reduction of neointimal growth in vein grafts
Clearly, further development of interventional devices is has also been reported after overexpression of a constitu-
essential to increase intracoronary gene transfer and to test tively active retinoblastoma protein [58]. A different
the role of gene therapy for restenosis. approach is to reduce SMC migration in vein grafts by
Another question relates to gene transfer efﬁcacy and overexpressing tissue inhibitors of metalloproteinases
safety in complex, lipid rich atherosclerotic arteries. (TIMP) 1 and 2 [59,60], the elastase inhibitor elaﬁn [61],
Adenovirus-mediated gene transfer of the marker gene or the senescent cell-derived inhibitor sdi-1 [62]. Coronary
human placental alkaline phosphatase was found equally arteriosclerosis in a mouse cardiac transplantation model
effective in human atherosclerotic vessels and in normal was prevented by transfer of antisense oligonucleotides
vessels in organ culture [40]. Anti-neointimal strategies against cyclin-dependent kinase CDK-2 [63].
have been successful in atherosclerotic rabbits [41]. How- Further insight in the arterial response to balloon-an-
ever, there might be some concern that adenoviral vectors gioplasty and stent implantation in patients will be neces-
may induce thrombosis in atherosclerotic arteries. Lafont sary to identify the best targets to reduce restenosis.
et al. [42] found that adenoviral gene transfer induced Continuous improvements in PTCA and stent implantation
b
y
 
g
u
e
s
t
 
o
n
 
N
o
v
e
m
b
e
r
 
3
,
 
2
0
1
4
D
o
w
n
l
o
a
d
e
d
 
f
r
o
m
 P. Sinnaeve et al. / Cardiovascular Research 44 (1999) 498–506 501
procedures, and the availability of intracoronary radiation atherosclerotic wall to reduce plaque progression or plaque
will need to be balanced against the added beneﬁt of gene rupture may therefore require less immunogenic vectors
therapy for restenosis. Possible candidates for gene therapy [75].
in vasculoproliferative disease include in-stent restenosis,
vein graft disease and transplant atherosclerosis.
5. Myocardial diseases
4. Hypercholesterolemia and atherosclerosis The incidence of congestive heart failure is increasing
[76] and despite advances in pharmacological treatment,
Atherosclerotic cardiovascular disease remains the lead- the associated morbidity and mortality remain high. There-
ing cause of death in western countries. Inherited disorders fore, gene-based strategies to improve cardiac function and
of lipoprotein metabolism often lead to lipid levels that are overall clinical outcome might be particularly useful for
difﬁcult to control with conventional lipid-lowering drugs, these patients.
making them particularly attractive targets for gene Gene-based approaches for heart failure are focusing on
therapy. Four years ago, the ﬁrst clinical study using ex proteins with a positive inotropic effect. Adenoviral gene
vivo gene therapy for familial hypercholesterolemia was transfer of a vasopressin receptor in cardiomyocytes
published [64]. Although signiﬁcant reductions of LDL potentiated myocardial contraction by bypassing the de-
levels in three out of ﬁve patients tested were observed for sensitized b-adrenergic receptor signaling [77], and over-
four months after gene transfer, to date no other clinical expression of phospholamban [78] or b2-adrenergic re-
studies have been initiated. ceptor [79] improved ventricular function in rodent hearts.
Gene therapy for atherosclerosis and hyperlipidemia has Gene transfer vectors with extended transgene expression
been focusing on modulating lipoprotein metabolism. proﬁles are required to effectively target heart failure. In
Successful attempts have been made to elevate HDL [65], this respect, intramyocardial or intracoronary injection of
and to decrease LDL [66], VLDL [67], and triglyceride recombinant adenovirus-associated vector encoding b-gal-
levels [68]. The effect of gene therapy on lipid proﬁles in actosidase resulted in signiﬁcant transgene expression
transgenic or knock-out mice lacking key components of levels for up to 8 weeks after the intervention, without
the lipoprotein metabolism has been amply reviewed [69]. evidence of myocardial inﬂammation or necrosis [80].
Gene-based techniques have also contributed to a better Myocardial infarction is a recent target for gene-based
understanding of the pathogenesis of atherosclerosis [70]. strategies, and reduction of reperfusion injury by over-
More recently, research has shifted to explore the effect of expressing antioxidative proteins might be a valuable
lipoprotein gene transfer on the development of the approach. Overexpression of extracellular superoxide dis-
atherosclerotic process itself [71]. Although larger animal mutase (ec-SOD) attenuated stunning in ischemic rabbit
models for atherosclerosis are under investigation, a proper hearts [81], and adenovirus-mediated cardiac gene transfer
interpretation of the effects of local genetic interventions of the antioxidant proteins SOD and catalase reduced
on the atherosclerotic process, plaque stability and plaque contractile dysfunction after ischemic reperfusion in the
progression remains very difﬁcult. This is mainly due to neonatal mouse heart [82]. Delivery of decoy double
the large variation and the unpredictability of lesions in stranded DNA against NFkB, a transcriptional factor that
these animals. Nevertheless, gene-based strategies for regulates cytokine and adhesion genes, reduced the extent
atherosclerosis and its complications will require ex- of myocardial infarction after reperfusion in the rat [83].
perimental scrutiny in relevant animal models before they However, gene transfer directly into infarcted myocardium
can be considered for clinical applications. suffers of low transfection efﬁciency when compared to
Alternative approaches to reduce atherosclerosis and its non-infarcted normal myocardium [84]. Further experi-
complications include the reduction of risk factors, e.g. the ments will have to determine the optimal delivery method
inhibition of apolipoprotein(a) expression, a known risk and time of delivery of candidate genes for the reduction
factor for atherosclerosis [72]. Novel non-lipoprotein- of necrosis after myocardial infarction.
based strategies, including overexpression of NOS with A completely different genetic approach to the treatment
subsequent reduction of inﬂammatory cell inﬁltration and of heart failure and myocardial infarction, is transfer of ex
lipid accumulation, might also be of interest [45]. The use vivo modiﬁed cells to the myocardium, as reviewed before
of gene therapy to stabilize arterial plaques might be a [85]. Primary cells were forced to differentiate into muscle
promising approach [73]. However, intravascular adminis- cells after overexpression of MyoD, a transcription factor
tration of the gene encoding b-galactosidase to brachial that drives myogenesis in non-muscle cells [86]. This
arteries of hypercholesterolemic monkeys increased vessel could in theory modify the phenotype of the failing heart,
wall inﬂammation and was associated with progression of provided that a sufﬁcient number of cells can be implanted
early atherosclerotic lesions [74]. This might have been without prohibitive toxicity. These obstacles have thus far
caused by the vector itself, or by an immunological limited the applicability of the technique in large animal
reaction to the transgene product. Gene transfer into the models.
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Gene therapy for inherited myocardial diseases still the multifactorial etiology of the disease and the very
suffers from many of the obstacles pointed out 2 years ago effective pharmacological therapy.
[87]. Targeting a sufﬁcient number of myocytes remains a In contrast, gene therapy for pulmonary hypertension
challenge, and several approaches are being contemplated might offer novel perspectives as pharmacological treat-
to improve efﬁcacy. Intracoronary injection is a fairly ment options are often limited. Adenovirus-mediated deliv-
straightforward approach, but leads only to very limited ery of constitutive NO Synthase via aerosol decreased both
transduction, with only 0.3% of the cells transfected with acute [103] and chronic hypoxia-induced pulmonary hy-
an adenoviral vector [88]. Pericardial delivery is under pertension in rats [104]. As extended transgene expression
investigation and has been combined with matrix degrad- is required for the treatment of chronic pulmonary hy-
ing proteins which facilitate the penetration of the visceral pertension, and because of uncertainties surrounding in-
pericardial barrier and markedly increase efﬁciency [89]. ﬂammatory reactions and immunogenicity of current vec-
Also, retrograde delivery via the sinus venosus during tors, improvements in vector design are necessary before
occlusion of the LAD has been shown to transduce 30– considering clinical applications.
50% of cardiomyocytes in the LAD region [90].
Recently, gene-based approaches have also been pro-
posed for the treatment of arrhythmias, both for acquired 8. New vectors
rhythm abnormalities (e.g. in heart failure or myocarditis
[91]) and for inherited diseases (e.g. the long QT To date, DNA and oligonucleotide-based treatments
syndromes [92] and familial atrial ﬁbrillation [93]). Im- have been very popular, probably due to less safety
proved delivery systems and vectors with longer and more concerns as compared with viral vectors, and have been
stable expression patterns will allow future investigations used in the ﬁrst clinical trials. However, at least one
in this ﬁeld. clinical trial has shown negative results, possibly because
of very low transduction rates [29]. Nevertheless, oligo-
nucleotide-based gene therapy strategies might have a
6. Thrombosis future [105]. Transfer of double stranded DNA that binds
essential transcription factors inhibits the activation of
In a review on gene therapy for arterial thrombosis [94], endogenous gene transcription by these factors [106]. This
the ﬁrst experiments to deliver antithrombotic genes strategy has been successfully used in a clinical trial of
(including hirudin, urokinase and cyclooxygenase) in prevention of vein graft failure [56]. New oligonucleotide
injured arteries were described. To date, several new genes design can improve vector performance. Ribozymes for
have been studied for their ability to reduce thrombosis. instance not only bind to complementary RNA sequences,
Adenoviral mediated overexpression of tPA [95], throm- but also cleave the sequence enzymatically, thereby am-
bomodulin [96], or tissue factor pathway inhibitor [97] plifying their effect, in contrast with conventional oligo-
reduced arterial thrombosis in injured rabbit arteries. These nucleotides. This novel method has been successfully used
genetic approaches need to be weighed against develop- in experimental models of in-stent restenosis [50].
ments in antithrombotic molecules (GP IIbIIIa antago- Although clearly more effective than naked DNA, viral
nists), which have signiﬁcantly improved the safety/efﬁca- vectors still suffer from local and systemic toxicity.
cy proﬁle of these drugs in patients suffering from acute Replication-defective adenoviruses are generated using a
coronary events [98]. Certainly, if local overexpression of helper cell-line that provides the missing E gene function. 1
antithrombotic gene products will further decrease bleed- Due to possible recombination events between sequences
ing complications associated with current systemic therapy in the vector and in the packaging helper cell-line, this
and retain therapeutic efﬁciency, this approach might be a method does not entirely exclude the generation of re-
valuable alternative. plication-competent adenoviral clones (RCA) during the
manufacturing process. As RCA may contribute signiﬁ-
cantly to adenovirus-related local and systemic toxicity,
7. Hypertension the development of a new helper cell-line [107] for the
generation of virus batches free of RCA has been a major
Genetic strategies based on inhibition of components of step towards future clinical use of these vectors. Because
the renin–angiotensin system are currently emerging to RCA have been implicated in the genesis of car-
treat systemic hypertension [99,100]. Intravenous injection diomyopathies, previous caveats on the use of viral vectors
of the gene encoding atrial natriuretic peptide (ANP) not in myocardial disease [87] will need to be reconsidered.
only attenuated hypertension in rats, but also decreased Thus vectors with additional deletions of adenoviral gene
cardiac hypertrophy and renal injury [101]. While gene sequences (E /E [108], E /E [109], E /E /E [110]) 2 A 41 41 3 4
transfer is certainly feasible and has shown proof of or vectors with all of the viral genes deleted (‘gutless’
principle [102], it seems nevertheless unlikely that it will vectors) have been constructed [111] and tested in animals,
replace pharmacological therapy in the near future, given often with conﬂicting results. However, proper engineering
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of viral genes will likely result in adenoviral vectors with including hypoxia-induced [124] or shear stress-sensitive
low toxicity and immunogenicity, and which will allow promoter sequences, or the viral vector envelope can be
prolonged expression and repeated administration. modiﬁed to increase tissue speciﬁcity. The retroviral
Adenovirus-associated virus (AAV)-derived vectors have envelope has been modiﬁed to incorporate the high afﬁnity
been proposed as a valuable alternative for cardiovascular collagen-binding domain from von Willebrand factor
gene therapy. AAV-derived vectors have some advantages [125], targeting the infection to the subendothelial matrix.
over adenoviral vectors, mainly because of their non- As vascular injury exposes collagen in the vessel wall, this
pathogenic nature and absence of inﬂammation, allowing vector might be particularly interesting to target damaged
stable, long-term expression [112]. Expression of a report- arteries.
er gene was observed in rat carotid arteries up to 6 months
after infection with AAV [113]. On the other hand, the
AAVgenome is small, only allowing room for about 4.8 kb 9. Conclusions
of added DNA, and the difﬁculties of reproducible ampliﬁ-
cation procedures to yield high titer AAV-derived vectors Cardiovascular gene therapy has reached the clinical
have limited this far the introduction of this vector in realm, and is likely to stay there. New clinical studies
cardiovascular disease models. Nevertheless, efforts to using gene therapy in patients with cardiovascular disease
improve infectious titer and yield [114] have initiated the are likely to emerge in the following years, particularly in
ﬁrst AAV cardiovascular gene therapy protocols in vitro the ﬁelds of restenosis, heart failure and angiogenesis.
[115] and in vivo [80,116]. Further insights in cardiovascular molecular biology will at
Retroviral vectors integrate into the host cell’s genome the same time provide new potential targets for gene-based
and result in a more stable and longer expression. They can strategies. Effective and safe delivery methods, together
only infect dividing cells and can theoretically induce with new vectors for target-speciﬁc binding or synthetic
malignant transformation by their random integration in formulations with high efﬁciency and safe proﬁle will
the host cell DNA. As for adenoviruses, one of the major undoubtedly lead to wider applicability of gene therapy in
concerns with retroviral vectors is the possibility that a cardiovascular disease. Despite our present lack of knowl-
replication-competent retrovirus is generated during the edge, intensiﬁed basic and applied research will certainly
manufacturing process. Nevertheless, retroviral vectors are bring the ﬁrst successes of cardiovascular gene-therapy
currently used for cardiovascular gene therapy protocols protocols in the years to come.
[99,117], and the advent of lentiviral vectors, which can
infect non-dividing cells [118] is expected to facilitate its
application for cardiovascular diseases. This is of par- Acknowledgements
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